114 related articles for article (PubMed ID: 9598136)
1. Iron binding capacity of didox (3,4 dihydroxybenzohydroxamic acid) and amidox (3,4 dihydroxybenzamidoxime) two inhibitors of the enzyme ribonucleotide reductase.
Fritzer-Szekeres M; Novotny L; Vachalkova A; Göbl R; Elford HL; Szekeres T
Adv Exp Med Biol; 1998; 431():599-604. PubMed ID: 9598136
[TBL] [Abstract][Full Text] [Related]
2. Iron binding capacity of didox (3,4-dihydroxybenzohydroxamic acid) and amidox (3,4-dihydroxybenzamidoxime) new inhibitors of the enzyme ribonucleotide reductase.
Fritzer-Szekeres M; Novotny L; Vachalkova A; Findenig G; Elford HL; Szekeres T
Life Sci; 1997; 61(22):2231-7. PubMed ID: 9393942
[TBL] [Abstract][Full Text] [Related]
3. Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4-dihydroxybenzamidoxime.
Tihan T; Elford HL; Cory JG
Adv Enzyme Regul; 1991; 31():71-83. PubMed ID: 1877400
[TBL] [Abstract][Full Text] [Related]
4. Genotoxic properties of the newly synthesized antineoplastic agents amidox, didox and trimidox.
Miadoková E; Macáková K; Podstavková S; Vlcek D
Pharmazie; 1997 Jul; 52(7):540-4. PubMed ID: 9266591
[TBL] [Abstract][Full Text] [Related]
5. Activation of caspases and induction of apoptosis by novel ribonucleotide reductase inhibitors amidox and didox.
Grusch M; Fritzer-Szekeres M; Fuhrmann G; Rosenberger G; Luxbacher C; Elford HL; Smid K; Peters GJ; Szekeres T; Krupitza G
Exp Hematol; 2001 May; 29(5):623-32. PubMed ID: 11376876
[TBL] [Abstract][Full Text] [Related]
6. Iron binding capacity of trimidox (3,4,5-trihydroxybenzamidoxime), a new inhibitor of the enzyme ribonucleotide reductase.
Szekeres T; Vielnascher E; Novotny L; Vachalkova A; Fritzer M; Findenig G; Göbl R; Elford HL; Goldenberg H
Eur J Clin Chem Clin Biochem; 1995 Nov; 33(11):785-9. PubMed ID: 8620054
[TBL] [Abstract][Full Text] [Related]
7. The new inhibitors of ribonucleotide reductase--comparison of some physico-chemical properties.
Romanova D; Vachalkova A; Szekeres T; Elford HL; Novotny L
J Pharm Biomed Anal; 1997 Apr; 15(7):951-6. PubMed ID: 9160261
[TBL] [Abstract][Full Text] [Related]
8. Amidox, an inhibitor of ribonucleotide reductase, potentiates the action of Ara-C in HL-60 human promyelocytic leukemia cells.
Bauer W; Horvath Z; Höchtl T; Saiko P; Karl D; Fritzer-Szekeres M; Szekeres T
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1541-4. PubMed ID: 15571294
[TBL] [Abstract][Full Text] [Related]
9. Interaction of gallium nitrate with other inhibitors of ribonucleotide reductase: effects on the proliferation of human leukemic cells.
Myette MS; Elford HL; Chitambar CR
Cancer Lett; 1998 Jul; 129(2):199-204. PubMed ID: 9719462
[TBL] [Abstract][Full Text] [Related]
10. Biochemical modulation of Ara-C effects by amidox, an inhibitor of ribonucleotide reductase in HL-60 promyelocytic human leukemia cells.
Höchtl T; Horvath Z; Bauer W; Karl D; Saiko P; Elford HL; Fritzer-Szekeres M; Szekeres T
Life Sci; 2004 Jan; 74(9):1071-80. PubMed ID: 14687648
[TBL] [Abstract][Full Text] [Related]
11. Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells.
Raje N; Kumar S; Hideshima T; Ishitsuka K; Yasui H; Chhetri S; Vallet S; Vonescu E; Shiraishi N; Kiziltepe T; Elford HL; Munshi NC; Anderson KC
Br J Haematol; 2006 Oct; 135(1):52-61. PubMed ID: 16925573
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML.
Cook GJ; Caudell DL; Elford HL; Pardee TS
PLoS One; 2014; 9(11):e112619. PubMed ID: 25402485
[TBL] [Abstract][Full Text] [Related]
13. Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells.
Horvath Z; Höchtl T; Bauer W; Fritzer-Szekeres M; Elford HL; Szekeres T; Tihan T
Cancer Chemother Pharmacol; 2004 Aug; 54(2):139-45. PubMed ID: 15133626
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of hemoglobin and F-cell production by targeting growth inhibition and differentiation of K562 cells with ribonucleotide reductase inhibitors (didox and trimidox) in combination with streptozotocin.
Iyamu WE; Adunyah SE; Fasold H; Horiuchi K; Elford HL; Asakura T; Turner EA
Am J Hematol; 2000 Apr; 63(4):176-83. PubMed ID: 10706760
[TBL] [Abstract][Full Text] [Related]
15. DNA-protective activity of new ribonucleotide reductase inhibitors.
Rauko P; Romanova D; Miadokova E; Macakova K; Novotny L; Elford HL; Szekeres T
Anticancer Res; 1997; 17(5A):3437-40. PubMed ID: 9413183
[TBL] [Abstract][Full Text] [Related]
16. In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity.
Mayhew CN; Phillips JD; Greenberg RN; Birch NJ; Elford HL; Gallicchio VS
Stem Cells; 1999; 17(6):345-56. PubMed ID: 10606163
[TBL] [Abstract][Full Text] [Related]
17. Ribonucleotide reductase inhibitors enhance cidofovir-induced apoptosis in EBV-positive nasopharyngeal carcinoma xenografts.
Wakisaka N; Yoshizaki T; Raab-Traub N; Pagano JS
Int J Cancer; 2005 Sep; 116(4):640-5. PubMed ID: 15818619
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase.
Szekeres T; Gharehbaghi K; Fritzer M; Woody M; Srivastava A; van't Riet B; Jayaram HN; Elford HL
Cancer Chemother Pharmacol; 1994; 34(1):63-6. PubMed ID: 8174204
[TBL] [Abstract][Full Text] [Related]
19. Effective use of ribonucleotide reductase inhibitors (Didox and Trimidox) alone or in combination with didanosine (ddI) to suppress disease progression and increase survival in murine acquired immunodeficiency syndrome (MAIDS).
Mayhew C; Oakley O; Piper J; Hughes NK; Phillips J; Birch NJ; Elford HL; Gallicchio VS
Cell Mol Biol (Noisy-le-grand); 1997 Nov; 43(7):1019-29. PubMed ID: 9449534
[TBL] [Abstract][Full Text] [Related]
20. The Antitumor Didox Acts as an Iron Chelator in Hepatocellular Carcinoma Cells.
Asperti M; Cantamessa L; Ghidinelli S; Gryzik M; Denardo A; Giacomini A; Longhi G; Fanzani A; Arosio P; Poli M
Pharmaceuticals (Basel); 2019 Sep; 12(3):. PubMed ID: 31480699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
